Ramon Salazar

TL;DR: B biomarker analyses of multiple studies strongly support the feasibility of refining risk stratification in colon cancer by factoring in molecular characteristics with pathologic tumor staging, and the value of BRAF or KRAS mutations as additional risk factors in stage III disease is greater when microsatellite status and tumor location are taken into account.

TL;DR: Cediranib activity, in terms of PFS and OS, was comparable to that of bevacizumab when added to mFOLFOX6; however, the predefined boundary for PFS noninferiority was not met.

TL;DR: The systems-level approach provides new insights into the micro-ecology of colorectal tumorogenesis, revealing a crosstalk between proteins secreted by the tumor and receptors activated in the adjacent colon tissue; and vice versa.

TL;DR: The development and validation of a genomic signature that identifies colorectal cancer patients with MSI caused by DNA mismatch repair deficiency with high accuracy is described and linked to a deficient MMR phenotype.

TL;DR: The expanding landscape of targetable oncogenic alterations and signatures in metastatic CRC is reviewed and the clinical implementation of novel molecular diagnostic tests are discussed.